Inquis Medical Completes Enrollment in Pivotal Trial of Aventus Thrombectomy System for Pulmonary Embolism
• Inquis Medical has completed enrollment in its AVENTUS Clinical Trial, a pivotal IDE trial for the Aventus Thrombectomy System, designed to treat pulmonary embolism (PE). • The trial enrolled 130 patients with intermediate-risk PE across more than 20 clinical sites in the United States. • The Aventus system features streamlined blood return and directional aspiration, potentially offering a more efficient thrombectomy solution. • The completion of enrollment marks a significant step toward a new treatment option for pulmonary embolism, addressing limitations of current procedures.

Stay Updated with Our Daily Newsletter
Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.
Related Topics
Reference News
Venous Thromboembolism (VTE) affects up to 900,000 in the U.S. annually, with over 50% of cases leading to pulmonary emb...
Inquis Medical completed patient enrollment for the AVENTUS Clinical Trial, evaluating the Aventus Thrombectomy System's...
Inquis Medical completed enrollment for a pivotal trial on its Aventus thrombectomy system, aimed at treating pulmonary ...
Inquis Medical completed enrollment of 130 patients in the AVENTUS Clinical Trial, evaluating the Aventus Thrombectomy S...